Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

• Type of Material: Article
• Authors: Amrita Krishnan, City of Hope National Medical Center; Ajay Nooka, Emory University; Ajai Chari, Icahn School of Medicine at Mount Sinai; Alfred L. Garfall, University of Pennsylvania; Thomas G. Martin, University of California San Francisco; Sandhya Nair, Janssen Pharmaceutica; Xiwu Lin, Janssen Global Services LLC; Keqin Qi, Janssen Research & Development; Anil Londhe, Janssen Research & Development; Lixia Pei, Janssen Research & Development; Eric Ammann, Janssen Global Services; Rachel Kobos, Janssen Research & Development; Jennifer Smit, Janssen Global Services; Trilok Parekh, Janssen Research & Development; Alexander Marshall, Janssen Global Services; Mary Slavcev, Janssen Global Services; Saad Z. Usmani, Memorial Sloan-Kettering Cancer Center
• Language: English
• Date: 2023-01-01
• Publisher: Janssen Global Services, LLC
• Publication Version: Final Published Version
• Copyright Statement: © 2023 Janssen Global Services, LLC
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.57264/cer-2022-0186
• Title of Journal or Parent Work: Journal of Comparative Effectiveness Research
• Volume: 12
• Issue: 6
• Start Page: e220186
• End Page: e220186
• Grant/Funding Information: he study was funded by Janssen Global Services, LLC.
• Keywords: Dexamethasone; Physicians; bispecific antibody; Treatment Outcome; indirect treatment comparison; MajesTEC-1; B-cell maturation antigen; Humans; Antineoplastic Combined Chemotherapy Protocols; comparative effectiveness; Multiple Myeloma; Antineoplastic Agents
• Research Categories: Health Sciences, Oncology; Biology, Cell

Abstract

We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59– 1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.